TheraPanacea is an innovative information technology company devoted to unlocking the power of AI-based solutions to drive innovation in healthcare.

A spin-off of University Paris-Saclay, TheraPanacea works in close cooperation with the most prominent healthcare facilities to combine the power of its proprietary platforms with clinical domain-knowledge.

Today, ART-Plan™, TheraPanacea dedicated suite for radio-oncology, is used by more than 60 cancer centres across Europe, Africa, Middle-East and the US and is helping to improve care for more than 60,000 patients every year.

TheraPanacea also develops and operates the ART-Omics™ platform enabling pharmaceutical companies to accelerate clinical research by harnessing AI-based multi-modality biomarker discovery in clinical trials and their effective integration within the clinical workflow at scale in the form of certified medical devices.

AI/ML

Health Care

Software

Therapeutics

TheraPanacea

Nikos Paragios

Baris Ungun, MD PhD

Thaís Roque, PhD/DPhil

Samia Achour

Rémi Vauclin

Rafael Marini Silva

Catherine Martineau-Huynh

Anne Walrafen

Alexandre Favre

Adam Manoli

The Clinical and Scientific Team at TheraPanacea collaborates with healthcare providers, pharmaceutical companies, and internal developers to integrate AI-based solutions within clinical workflows. This team is responsible for analyzing clinical data, managing and implementing AI solutions in radiation oncology, coordinating clinical trials, and ensuring the ART-Plan™ and ART-Omics™ platforms are effectively utilized to drive research and improve patient care outcomes. They also market and support these solutions to enhance clinical adoption and sales.

Clinical and Scientific Team

Engineering Team

Leadership Team

Clinical and Scientific Team

About

Team members

Other teams at TheraPanacea

Engineering Team

Leadership Team